SCHEMBL23199730

SCHEMBL23199730

CCOc1ccc(N2CC3(C)CNCC3(C)C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
ALDH1A1 P00352 4/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
TP53 P04637 1/20 0.53
BACE1 P56817 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NQO1 P15559 1/20 0.47
LMNA P02545 2/20 0.46
GAA P10253 4/20 0.46
KMT2A Q03164 4/20 0.43
MEN1 O00255 2/20 0.43
ALOX15 P16050 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.43
APP P05067 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
SNCA P37840 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701464 1.00 MAPT (0.53) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL23701456 0.78 TSHR (0.45) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL23701454 0.78 TSHR (0.45) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL23732400 0.77 POLB (0.55) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL23199736 0.77 POLB (0.55) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL27363642 0.76 MAPT (0.65) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL11503962 0.76 MAPT (0.65) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL2155052 0.76 ADRB1 (0.66) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL25391026 0.75 POLB (0.42) ALDH1A1L3MBTL1POLBTSHR
Hydrochloric Acid SCHEMBL27331131 0.75 ADRB1 (0.64) MAPTALDH1A1NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed
EP-3802541-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS The Institute of Cancer Research: Royal Cancer Hospital (GB) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 MAPT 4829/4885ALDH1A1 765/4885NPC1 3979/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 MAPT 4829/4885ALDH1A1 765/4885NPC1 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.